Eptifibatide Patent Expiration
Eptifibatide is Used for preventing blood clot formation in patients with platelet-associated ischemic disorders. It was first introduced by Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc
Eptifibatide Patents
Given below is the list of patents protecting Eptifibatide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Integrilin | US5807825 | Platelet aggregation inhibitors |
Sep 15, 2015
(Expired) | Msd Sub Merck |
| Integrilin | US5968902 | Platelet aggregation inhibitors |
Jun 02, 2015
(Expired) | Msd Sub Merck |
| Integrilin | US5747447 | Stable polypeptide composition |
May 05, 2015
(Expired) | Msd Sub Merck |
| Integrilin | US5686570 | Platelet aggregation inhibitors |
Nov 11, 2014
(Expired) | Msd Sub Merck |
| Integrilin | US5756451 | Platelet aggregation inhibitors |
Nov 11, 2014
(Expired) | Msd Sub Merck |
Eptifibatide's Family Patents
Explore Our Curated Drug Screens
Eptifibatide Generic API Manufacturers
Several generic applications have been filed for Eptifibatide. The first generic version for Eptifibatide was by Teva Pharmaceuticals Usa and was approved on Jun 5, 2015. And the latest generic version is by Hong Kong King Friend Industrial Co Ltd and was approved on May 9, 2024.
Given below is the list of companies who have filed for Eptifibatide generic, along with the locations of their manufacturing plants worldwide.
1. ACCORD HLTHCARE
Accord Healthcare Inc has filed for 2 different strengths of generic version for Eptifibatide. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 75MG/100ML | injectable | Discontinued | INJECTION | N/A | Nov 6, 2017 |
| 2MG/ML | injectable | Discontinued | INJECTION | N/A | Nov 6, 2017 |
2. AMNEAL PHARMS
Amneal Pharmaceuticals Of New York Llc has filed for 2 different strengths of generic version for Eptifibatide. Given below are the details of the strengths of this generic introduced by Amneal Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 75MG/100ML | injectable | Discontinued | INJECTION | N/A | Dec 8, 2016 |
| 2MG/ML | injectable | Discontinued | INJECTION | N/A | Dec 8, 2016 |
3. BAXTER HLTHCARE CORP
Baxter Healthcare Corp has filed for 2 different strengths of generic version for Eptifibatide. Given below are the details of the strengths of this generic introduced by Baxter Hlthcare Corp.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2MG/ML | injectable | Discontinued | INJECTION | N/A | Nov 23, 2018 |
| 75MG/100ML | injectable | Prescription | INJECTION | AP | Nov 23, 2018 |
4. EUGIA PHARMA
Eugia Pharma Specialities Ltd has filed for 2 different strengths of generic version for Eptifibatide. Given below are the details of the strengths of this generic introduced by Eugia Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 75MG/100ML | injectable | Prescription | INJECTION | AP | Dec 8, 2015 |
| 2MG/ML | injectable | Prescription | INJECTION | AP | Dec 8, 2015 |
Manufacturing Plant Locations New
Eugia Pharma's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Eugia Pharma as present at those locations.
| Country | City | Firm Name | ||||||
|---|---|---|---|---|---|---|---|---|
| India |
| |||||||
5. HONG KONG
Hong Kong King Friend Industrial Co Ltd has filed for 2 different strengths of generic version for Eptifibatide. Given below are the details of the strengths of this generic introduced by Hong Kong.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2MG/ML | injectable | Prescription | INJECTION | AP | May 9, 2024 |
| 75MG/100ML | injectable | Prescription | INJECTION | AP | May 9, 2024 |
Manufacturing Plant Locations New
Hong Kong's manufacturing plants are situated in 2 countries - United States, Hong Kong SAR. Given below are the details of these plant locations as well as the firm names of Hong Kong as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||
| Hong Kong SAR |
| |||||||||
6. HYBIO
Hybio Pharmaceutical Co Ltd has filed for 2 different strengths of generic version for Eptifibatide. Given below are the details of the strengths of this generic introduced by Hybio.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 75MG/100ML | injectable | Discontinued | INJECTION | N/A | Mar 20, 2020 |
| 2MG/ML | injectable | Discontinued | INJECTION | N/A | Mar 20, 2020 |
Manufacturing Plant Locations New
Hybio's manufacturing plants are situated in 1 country - China. Given below are the details of these plant locations as well as the firm names of Hybio as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| China |
| |||
7. MYLAN LABS LTD
Mylan Laboratories Ltd has filed for 2 different strengths of generic version for Eptifibatide. Given below are the details of the strengths of this generic introduced by Mylan Labs Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 75MG/100ML
(reference standard) | injectable | Prescription | INJECTION | AP | Jul 20, 2018 |
| 2MG/ML
(reference standard) | injectable | Prescription | INJECTION | AP | Jul 20, 2018 |
8. RISING
Rising Pharma Holdings Inc has filed for 2 different strengths of generic version for Eptifibatide. Given below are the details of the strengths of this generic introduced by Rising.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2MG/ML | injectable | Discontinued | INJECTION | N/A | Apr 18, 2017 |
| 75MG/100ML | injectable | Discontinued | INJECTION | N/A | Apr 18, 2017 |
Manufacturing Plant Locations New
Rising's manufacturing plants are situated in 3 countries - United States, Mexico, India. Given below are the details of these plant locations as well as the firm names of Rising as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||||
| Mexico |
| |||||||||||||||||||
| India |
| |||||||||||||||||||
9. SAGENT PHARMS INC
Sagent Pharmaceuticals Inc has filed for 2 different strengths of generic version for Eptifibatide. Given below are the details of the strengths of this generic introduced by Sagent Pharms Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 75MG/100ML | injectable | Prescription | INJECTION | AP | Mar 7, 2018 |
| 2MG/ML | injectable | Prescription | INJECTION | AP | Mar 7, 2018 |
10. SHUANGCHENG
Hainan Shuangcheng Pharmaceuticals Co Ltd has filed for 2 different strengths of generic version for Eptifibatide. Given below are the details of the strengths of this generic introduced by Shuangcheng.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2MG/ML | injectable | Prescription | INJECTION | AP | Sep 7, 2021 |
| 75MG/100ML | injectable | Prescription | INJECTION | AP | Apr 20, 2022 |
11. SLATE RUN PHARMA
Slate Run Pharmaceuticals Llc has filed for 2 different strengths of generic version for Eptifibatide. Given below are the details of the strengths of this generic introduced by Slate Run Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 75MG/100ML | injectable | Prescription | INJECTION | AP | Jan 25, 2019 |
| 2MG/ML | injectable | Prescription | INJECTION | AP | Jan 25, 2019 |
12. TEVA PHARMS USA
Teva Pharmaceuticals Usa has filed for 2 different strengths of generic version for Eptifibatide. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 75MG/100ML | injectable | Discontinued | INJECTION | N/A | Jun 5, 2015 |
| 2MG/ML | injectable | Prescription | INJECTION | AP | Jun 12, 2015 |
13. USV
Usv Private Ltd has filed for 2 different strengths of generic version for Eptifibatide. Given below are the details of the strengths of this generic introduced by Usv.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2MG/ML | injectable | Discontinued | INJECTION | N/A | Mar 14, 2019 |
| 75MG/100ML | injectable | Discontinued | INJECTION | N/A | Mar 14, 2019 |
Manufacturing Plant Locations New
Usv's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Usv as present at those locations.
| Country | City | Firm Name | ||||||
|---|---|---|---|---|---|---|---|---|
| India |
| |||||||